Morais HG, Costa CS, Gonçalo RI, Carlan LM, Morais EF, Galvão HC, et al. Biological role of the bidirectional interaction between epithelial-mesenchymal transition and PD-L1 expression in head and neck squamous cell carcinomas: A systematic review. Med Oral Patol Oral Cir Bucal. 2023 Jul 1;28 (4):e395-403.
doi:10.4317/medoral.25810
https://dx.doi.org/doi:10.4317/medoral.25810
1. Min AK, Okayama H, Saito M, Ashizawa M, Aoto K, Nakajima T, et al. Epithelial-mesenchymal transition-converted tumor cells can induce T-cell apoptosis through upregulation of programmed death ligand 1 expression in esophageal squamous cell carcinoma. Cancer Med. 2018;7:3321-30. |
PMid:29855157 PMCid:PMC6051241 |
2. Li H, Liu YT, Chen L, Zhou JJ, Chen DR, Li SJ, et al. CMTM4 regulates epithelial-mesenchymal transition and PD-L1 expression in head and neck squamous cell carcinoma. Mol Carcinog. 2021;60:556-66. |
PMid:34061408 |
3. Mahmoudian RA, Mozhgani S, Abbaszadegan MR, Mokhlessi L, Montazer M, Gholamin M. Correlation between the immune checkpoints and EMT genes proposes potential prognostic and therapeutic targets in ESCC. J Mol Histol. 2021;52:597-609. |
PMid:33884540 |
4. Eichberger J, Schulz D, Pscheidl K, Fiedler M, Reichert TE, Bauer RJ, et al. PD-L1 influences cell spreading, migration and invasion in head and neck cancer cells. Int J Mol Sci. 2020;21:8089. |
PMid:33138288 PMCid:PMC7663567 |
5. Jung AR, Jung CH, Noh JK, Lee YC, Eun YG. Epithelial-mesenchymal transition gene signature is associated with prognosis and tumor microenvironment in head and neck squamous cell carcinoma. Sci Rep. 2020;10:3652. |
PMid:32107458 PMCid:PMC7046610 |
6. Fei Z, Deng Z, Zhou L, Li K, Xia X, Xie R. PD-L1 induces epithelial-mesenchymal transition in nasopharyngeal carcinoma cells through activation of the PI3K/AKT pathway. Oncol Res. 2019;27:801-7. |
PMid:30982497 PMCid:PMC7848446 |
7. Zhang H, Qin G, Zhang C, Yang H, Liu J, Hu H, et al. TRAIL promotes epithelial-to-mesenchymal transition by inducing PD-L1 expression in esophageal squamous cell carcinomas. J Exp Clin Cancer Res. 2021;40:209. |
PMid:34167551 PMCid:PMC8223376 |
8. Hirai M, Kitahara H, Kobayashi Y, Kato K, Bou-Gharios G, Nakamura H, et al. Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment. Int J Oncol. 2017;50:41-8. |
PMid:27922697 PMCid:PMC5182007 |
9. Dong P, Xiong Y, Yue J, Hanley SJB, Watari H. Tumor-intrinsic PD-L1 signaling in cancer initiation, development and treatment: beyond immune evasion. Front Oncol. 2018;8:386. |
PMid:30283733 PMCid:PMC6156376 |
10. Moher D, Liberati A, Tetzlaff J, Altman DG (PRISMA Group). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Int J Surg. 2010;8:336-41. |
PMid:20171303 |
11. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383-94. |
PMid:21195583 |
12. Huguet A, Hayden JA, Stinson J, McGrath PJ, Chambers CT, Tougas ME, et al. Judging the quality of evidence in reviews of prognostic factor research: Adapting the GRADE framework. Syst Rev. 2013;2:71. |
PMid:24007720 PMCid:PMC3930077 |
13. Pavan LM., Rego DF, Elias ST, De Luca Canto G, Guerra EN. In vitro anti-tumor effects of statins on head and neck squamous cell carcinoma: A systematic review. PloS One. 2015;10:e0130476. |
PMid:26098683 PMCid:PMC4476585 |
14. Chen L, Xiong Y, Li J, Zheng X, Zhou Q, Turner A, et al. PD-L1 expression promotes epithelial to mesenchymal transition in human esophageal cancer. Cell Physiol Biochem. 2017;42:2267-80. |
PMid:28848143 |
15. Tsutsumi S, Saeki H, Nakashima Y, Ito S, Oki E, Morita M, et al. Programmed death-ligand 1 expression at tumor invasive front is associated with epithelial-mesenchymal transition and poor prognosis in esophageal squamous cell carcinoma. Cancer Sci. 2017;108:1119-27. |
PMid:28294486 PMCid:PMC5480087 |
16. Cui P, Jing P, Liu X, Xu W. Prognostic significance of PD-L1 expression and its tumor-intrinsic functions in hypopharyngeal squamous cell carcinoma. Cancer Manag Res. 2020;12:5893-902. |
PMid:32765090 PMCid:PMC7373417 |
17. Cui B, Chen J, Luo M, Liu Y, Chen H, Lü D, et al. PKD3 promotes metastasis and growth of oral squamous cell carcinoma through positive feedback regulation with PD-L1 and activation of ERK-STAT1/3-EMT signalling. Int J Oral Sci. 2021;13:8. |
PMid:33692335 PMCid:PMC7946959 |
18. Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res. 2005;11:2947-53. |
PMid:15837746 |
19. Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer. 2010;116:1757-66. |
PMid:20143437 |
20. Azuma K, Ota K, Kawahara A, Hattori S, Iwama E, Harada T, et al. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann Oncol. 2014;25:1935-40. |
PMid:25009014 |
21. Wang Q, Lou W, Di W, Wu X. Prognostic value of tumor PD-L1 expression combined with CD8+ tumor infiltrating lymphocytes in high grade serous ovarian cancer. Int Immunopharmacol. 2017;52:7-14. |
PMid:28846888 |
22. Kok VC. Current understanding of the mechanisms underlying immune evasion from PD-1/PD-L1 immune checkpoint blockade in head and neck cancer. Front Oncol. 2020;10:268. |
PMid:32185135 PMCid:PMC7058818 |
23. Akin TT, Bregni G, Camera S, Deleporte A, Hendlisz A, Sclafani F. PD-1 and PD-L1 inhibitors in oesophago-gastric cancers. Cancer Lett. 2020;469:142-50. |
PMid:31669518 |
24. Ferris RL, Blumenschein GJ, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856-1867. |
PMid:27718784 PMCid:PMC5564292 |
25. Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): A randomised, open-label, phase 3 study. Lancet. 2019;393:156-167. |
PMid:30509740 |
26. Davar D, Wang H, Chauvin JM, Pagliano O, Fourcade JJ, Ka M, et al. Phase Ib/II study of pembrolizumab and pegylated-interferon alfa-2b in advanced melanoma. J Clin Oncol. 2018;36:JCO1800632. |
PMid:30359157 PMCid:PMC6286160 |
27. Morais EF, Rolim LSA, Almeida DRMF, Morais HGF, Souza LB, Freitas RA. Biological role of epithelial-mesenchymal-transition-inducing transcription factors in head and neck squamous cell carcinoma: A systematic review. Arch Oral Biol. 2020;119:104904. |
PMid:32947165 |
28. Morais HGF, Morais EF, Carlan LM, Santos HBPS, Silveira ÉJD, Freitas RA. Epithelial-mesenchymal transition modulates lower lip carcinogenesis and promotes cancer progression. Arch Oral Biol. 2022;136:105387. |
PMid:35240445 |
29. de Streel G, Bertrand C, Chalon N, et al. Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer. Nat Commun. 2020;11:4545. |
PMid:32917858 PMCid:PMC7486376 |
30. Chang E, Pelosof L, Lemery S, Gong Y, Goldberg KB, Farrell AT, et al. Systematic review of PD-1/PD-L1 inhibitors in oncology: from personalized medicine to public health. Oncologist. 2021;26:e1786-99. |
PMid:34196068 PMCid:PMC8488782 |